Kura Oncology, Inc. (KURA) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
KURA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KURA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.9% | -449.9% | -412.9% |
| 2024 | 100.0% | -358.5% | -322.9% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export KURA earnings history in CSV or JSON format
Free sign-in required to download data
Kura Oncology, Inc. (KURA) Earnings Overview
As of May 8, 2026, Kura Oncology, Inc. (KURA) reported trailing twelve-month net income of -$279M, reflecting -57.4% year-over-year growth. The company earned $-3.16 per diluted share over the past four quarters, with a net profit margin of -412.9%.
Looking at the long-term picture, KURA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$19,996 in fiscal 2009.
Kura Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MGNX (-$75M net income, -49.9% margin), TPVG (-$12M net income, 50.6% margin), AGIO (-$423M net income, -764.0% margin), KURA has room to improve margins relative to the peer group. Compare KURA vs MGNX →
KURA Earnings vs Peers
Earnings metrics vs comparable public companies
KURA Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$279M | -60.2% | -$304M | $-3.18 | -412.9% | -449.9% |
| 2024 | -$174M | -14.0% | -$193M | $-2.02 | -322.9% | -358.5% |
| 2023 | -$153M | -12.4% | -$166M | $-2.08 | - | - |
| 2022 | -$136M | -4.1% | -$140M | $-2.03 | - | - |
| 2021 | -$130M | -45.6% | -$131M | $-1.97 | - | - |
| 2020 | -$90M | -41.9% | -$92M | $-1.69 | - | - |
| 2019 | -$63M | -4.5% | -$67M | $-1.51 | - | - |
| 2018 | -$60M | -70.6% | -$63M | $-1.72 | - | - |
| 2017 | -$35M | -28.6% | -$36M | $-1.52 | - | - |
| 2016 | -$28M | -21.8% | -$28M | $-1.47 | - | - |
See KURA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KURA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KURA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKURA — Frequently Asked Questions
Quick answers to the most common questions about buying KURA stock.
Is KURA growing earnings?
KURA EPS fell to $-3.16, with earnings declining -57.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-279M.
What are KURA's profit margins?
Kura Oncology, Inc. net margin is -412.9%, with operating margin at -449.9%. Below-average margins reflect competitive or cost pressures.
How consistent are KURA's earnings?
KURA earnings data spans 2008-2025. The declining earnings trend is -57.4% YoY. Historical data enables comparison across business cycles.